Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil PK in Healthy Japanese Men
NCT04075409Phase 1Completed
- Sponsor
- UCB
- Start
- Sep 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of padsevonil in focal epilepsy (3 arms), sponsored by UCB. Primary endpoints: Maximum Plasma Concentration (Cmax) of a Single Dose Padsevonil, Area Under the Curve From 0 to t (AUC(0-t)) of a Single Dose Padsevonil and 8 more. Started Sep 2019; status: completed.
02
Drugs
padsevonil
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT04075409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075409.